Welcome to our dedicated page for Agilon Health news (Ticker: AGL), a resource for investors and traders seeking the latest updates and insights on Agilon Health stock.
agilon health, inc. provides a healthcare services platform that partners with primary care physician groups and health systems to transition senior patient care to a value-based Total Care Model. Company updates commonly cover Medicare Advantage members and ACO model beneficiaries on the agilon platform, payor contract economics, market exits, clinical programs, data and technology investments, and operating discipline within a Medicare-centric capitated care model.
News also includes quarterly and annual financial results, revenue, medical margin and Adjusted EBITDA guidance, conference participation, and governance changes such as CEO appointments and board membership. Recurring disclosures tie membership trends, payor alignment and clinical execution to the economics of agilon’s physician partnerships.
agilon health (NYSE: AGL) reported first-quarter 2026 results and raised full-year guidance on May 6, 2026. Key first-quarter metrics: total revenues $1.42B, medical margin $149M, Adjusted EBITDA $54M, and total members 536,000 as of March 31, 2026.
The company raised 2026 guidance for total revenues, medical margin, and Adjusted EBITDA, and noted cash, cash equivalents and marketable securities of $303M and total debt of $32M.
agilon health (NYSE: AGL) appointed Tim O’Rourke as Chief Executive Officer and board member, effective May 7, 2026. He succeeds Ronald A. Williams, who will continue as Chairman of the Board.
O’Rourke brings 25+ years in payor and value-based care, including roles as President of Help at Home, 17 years at Humana, and CEO of Ascension Complete. The Board said the hire follows a year of operational and financial transformation and aims to build on improved data, contracting, and clinical capabilities.
agilon health (NYSE: AGL) will report Q1 2026 financial results after market close on Wednesday, May 6, 2026 and host a conference call at 4:30 p.m. ET.
According to the company, U.S. participants may dial (833) 461-5787, international participants +1 (585) 542-9983, participant code 206810108, and a simultaneous webcast and replay are available via agilon's Investor Relations "Events & Presentations" page.
agilon health (NYSE: AGL) will implement a 1-for-25 reverse stock split effective March 30, 2026 (around 5:01 p.m. ET), with split-adjusted trading expected to begin March 31, 2026 under the existing ticker AGL. The split reduces outstanding shares to approximately 16,605,993 and issues no fractional shares (cash paid in lieu).
The Board approved the 1-for-25 ratio following stockholder authorization for a 1-for-5 to 1-for-25 range. The split aims to raise the share price above $1.00 to meet NYSE minimum bid requirements, and proportional adjustments were made to equity incentive awards and outstanding option terms. New CUSIP is 00857U206.
agilon health (NYSE: AGL) reported Q4 2025 revenue of $1.57B (+3% YoY) and fiscal 2025 revenue of $5.93B (-2% YoY). The company posted a Q4 net loss of $189M and FY net loss of $391M, with FY Adjusted EBITDA loss of $296M. Total members declined to 625,000. Cash and marketable securities were $285M with total debt of $35M. 2026 guidance targets revenue of $5.41–$5.58B, medical margin $300–$350M and Adjusted EBITDA range implying a mid‑point around breakeven.
agilon health (NYSE: AGL) announced management will participate in three investor conferences in March 2026: Cowen on March 2, Jefferies on March 9, and Barclays on March 10. Webcasts will be available for Cowen and Barclays; Jefferies will not provide a webcast due to event format.
Replays and on‑demand audio will be posted in the company’s Events & Presentations section on its investor relations website shortly after each presentation.
agilon health (NYSE: AGL) will release its fourth quarter and full year 2025 financial results after market close on Wednesday, February 25, 2026. The company will host a conference call at 4:30 p.m. ET the same day to discuss results. U.S. participants can dial (833) 470-1428, international participants +1 (404) 975-4839, using participant code 868078. A simultaneous webcast will be available in the Events & Presentations section of agilon's investor relations website at https://investors.agilonhealth.com, and a replay will be posted for on-demand listening shortly after the call.
agilon health (NYSE: AGL) said its management team will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025 at 3:00 PM ET. Investors can listen via a simultaneous webcast on the company’s Events & Presentations page at the investor relations website. Replays will be posted for on-demand listening shortly after the presentation.
agilon health (NYSE: AGL) announced on November 7, 2025 that the New York Stock Exchange issued a notice dated November 5, 2025 saying the company is no longer in compliance with the NYSE continued listing Price Criteria because the average closing price was under $1.00 over a consecutive 30 trading-day period ended November 4, 2025.
The notice does not have immediate impact on the listing, and the company said operations and SEC reporting are not anticipated to be affected. agilon intends to notify the NYSE by November 19, 2025 that it will remain listed and plans to pursue a reverse stock split to regain compliance, subject to stockholder approval at the 2026 annual general meeting.
agilon health (NYSE: AGL) reported third-quarter 2025 results and re-established full-year outlook on November 4, 2025. Q3 revenue was $1.44B (down 1% YoY) with gross loss $68M, net loss $110M and Adjusted EBITDA loss $91M. Total members stood at 618,000 (6% decline YoY) including 503,000 Medicare Advantage and 115,000 ACO REACH beneficiaries.
The company cited a $73M shortfall in 2025 risk adjustment revenue (including a 9-month true-up), a $20M Q3 impact from exited markets and expects exited-market impact of $60M for the year. Cash and marketable securities were $311M and total debt $35M. Management expects $30M of operating cost reductions in 2026 and reiterated 2025 revenue guidance of $5.81B–$5.83B with Adjusted EBITDA of ($270M)–($245M).